Telangana will support research initiatives: Minister Danasari Anasuya

HYDERABAD: Research and surveys play an important role in shaping government policies and welfare schemes, said Women and Child Welfare Minister Danasari Anasuya, also known as Seethakka.
She was speaking after releasing the Young Lives Round-7 survey report at the Centre for Economic and Social Studies (CESS) campus in Begumpet on Friday.
The minister acknowledged CESS for conducting a comprehensive study on indicators such as education, health, nutrition, learning ability, work and family conditions. She stated that the findings from field-based surveys are useful in identifying gaps in existing policies and can contribute to policy formulation and revisions.
Seethakka noted the government's focus on improving education, healthcare and nutrition, particularly for underprivileged and tribal communities.
Recalling her own childhood, she said she was familiar with the experience of hunger as a tribal child and added that efforts are being made to address nutritional deficiencies among school children in tribal regions. She said government hostels and schools are being upgraded with improved facilities and meals.
The minister described malnutrition as a major barrier to development in tribal areas and referred to the government's initiative of distributing nutrient-rich chikkis to help girls tackle anaemia.
Seethakka underlined the role of evidence-based surveys in highlighting public issues, developmental needs, and gaps in governance. She said the Congress government in Telangana would support such research initiatives.
Others present at the event included Economic and Political Weekly editor and ICFAI School of Social Sciences professor S Mahendra Dev, CESS director and Young Lives India principal investigator E Revathi, NHM representative Dr Padmaja and Young Lives India country director Renu Singh.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

First Post

10-06-2025

• First Post

Explained: What is the new XFG variant detected in India amid rising Covid cases?

A newly emerging strain called 'XFG' has now been detected in India, with the Covid-19 case tally surpassing 6,500. According to Insacog, the government agency monitoring the different variants, as many as 163 cases of the XFG variant have been reported in India so far, with the most from Maharashtra (89). Is there a reason to worry? read more According to the Insacog, 163 cases of the XFG variant have been reported across India so far. Image for Representation. Pixabay India is once again seeing a rise in Covid-19 cases, and this time, a new sub-variant is also in the mix. While the JN.1 variant of Omicron has been around for a while, a newly emerging strain called 'XFG' has now been detected in the country, raising fresh concerns as infections are creeping up again. According to the Indian SARS-CoV-2 Genomics Consortium (Insacog), which monitors how the virus which causes Covid-19 evolves, as many as 163 cases of the XFG variant have been reported across India so far. STORY CONTINUES BELOW THIS AD This rise in cases comes alongside a steady climb in active infections across the country. According to the Union Health Ministry, India has now recorded over 6,500 active Covid-19 cases, with 769 new cases reported in just the last 48 hours. So, what exactly is this XFG variant? And does it pose a serious threat? Are vaccines effective against the new variant? Here's what we know so far Covid-19 in India: What is the XFG variant? The XFG variant is a recombinant subvariant of the SARS-CoV-2 virus—essentially, it's the result of two earlier strains, LF.7 and LP.8.1.2, merging together. Recombinant variants like XFG typically emerge when someone is infected with two different versions of the virus at the same time, allowing the virus to 'mix and match' its genetic code. The XFG variant is a recombinant subvariant of the SARS-CoV-2 virus—essentially, it's the result of two earlier strains, LF.7 and LP.8.1.2, merging together. Representational Image According to The Lancet journal, XFG falls under the Omicron family of Covid-19 variants, which has been the dominant global strain since late 2021. It was first detected in Canada. The study also points out that the XFG variant shows 'strong immune evasion'—meaning it has the ability to dodge the body's natural immune defences, helping it survive longer and spread more easily. Where are the XFG cases in India? The latest data from Insacog shows that India has reported 163 cases of the XFG variant so far. Maharashtra has recorded the highest number with 89 cases, followed by Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh, and West Bengal, each with six cases. STORY CONTINUES BELOW THIS AD Telangana is the newest state on the list, with one confirmed case. The latest data from Insacog shows that India has reported 163 cases of the XFG variant so far. Maharashtra has recorded the highest number of the XFG variant with 89 cases. Image for Representation/ PTI Most of these infections—159 cases—were detected in May 2024, while two each were reported in April and June. Is there a reason to worry? For now, the answer seems to be no. There is currently no evidence suggesting that the XFG variant causes more severe illness or leads to higher death rates compared to other Omicron sub-variants. As with most strains that evolved from Omicron, XFG is mostly associated with mild upper respiratory symptoms, particularly in people who are vaccinated or have previously recovered from Covid-19. So far, XFG has not been labelled a Variant of Concern (VOC) or Variant of Interest (VOI) by either the World Health Organisation (WHO) or India's Ministry of Health. That means it hasn't been linked to serious outbreaks, a rise in hospitalisations, or issues with vaccine effectiveness—at least not yet. That said, health experts remain cautious. The virus is still evolving, and variants that evade immunity or develop mutations that improve their ability to bind to human cells (especially through the spike protein) could cause future waves if not closely watched. STORY CONTINUES BELOW THIS AD There is currently no evidence suggesting that the XFG variant causes more severe illness or leads to higher death rates compared to other Omicron sub-variants. Image for Representation. AFP 'According to Indian Council of Medical Research (ICMR) data, 66 per cent of current respiratory viral infections in India are Covid-related. However, hospitalisation is low, including in Telangana. People with two or more comorbidities, weakened immunity, or above 70 years should remain alert,' Dr Kiran Madala, who is also a professor at Gandhi Medical College, told The Times of India. Are vaccines effective against the XFG variant? The good news is that India's current Covid-19 vaccines, including Covaxin, Covishield, and the newer booster shots, are still believed to provide protection against severe illness and hospitalisation from the XFG variant. Health experts say that while mild breakthrough infections can still occur, especially as antibody levels decline over time, the T-cell immunity developed through vaccination is likely to stay effective. Covid-19 cases cross the 6,500 mark According to the Ministry of Health and Family Welfare, India's active Covid-19 cases have now surpassed 6,500, pointing to a steady uptick in infections. The Ministry also confirmed 65 Covid-related deaths across Uttar Pradesh, West Bengal, Tamil Nadu, Punjab, Maharashtra, Madhya Pradesh, Kerala, Karnataka, Gujarat, and Delhi. Kerala has emerged as the worst-hit state, with 1,957 active cases and seven new infections reported in just the last 24 hours. Amid the surge, the state government has made Covid-19 testing mandatory for individuals showing symptoms. They have also released updated guidelines, urging the public to take all necessary precautions. STORY CONTINUES BELOW THIS AD With input from agencies

New Indian Express

10-06-2025

• New Indian Express

Free health tests to be provided to poor children: Telangana Minister Seethakka

HYDERABAD: The state government will soon be rolling out a new scheme for children. Women and Child Welfare Minister D Anasuya alias Seethakka has announced that under the new scheme 'Bala Bharosa', the state government will conduct health tests on all children aged between zero and five. After conducting tests, the government will provide free treatment to the children who are in need. The minister, along with Chief Secretary K Ramakrishna Rao, held a video conference with the district collectors on progress of 'Indira Mahila Shakti' programme from the state Secretariat here on Monday. During the conference, she instructed the officials to identify the lands for setting up of solar plants and petrol pumps to be managed by SHG groups, as agreements have already been made for this with companies.

The Hindu

09-06-2025

• The Hindu

COVID-19's Return: New Variants, Mild Symptoms, and the Gaps in India's Public Health Preparedness

Published : Jun 09, 2025 17:07 IST - 7 MINS READ COVID-19 is once again making headlines. As of June 9, India has 6,491 active cases, according to the Union Health Ministry. Kerala remains the most affected State with 1,957 cases as of June 6, followed by Gujarat (980), West Bengal (747), and Delhi (728). While hospitalisations remain low and most cases are mild, the government has increased surveillance, testing, and hospital preparedness. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), one case of the NB.1.8.1 variant was found in Tamil Nadu in April, and four cases of LF.7 were reported in Gujarat in May. The dominant variant in the country is JN.1, which is highly transmissible but generally mild, accounting for 53 per cent of current cases. 'When COVID first came, it was hugely problematic. We weren't prepared for it,' said Dr. Sylvia Karpagam. 'But now it can be endemic, in the sense that the virus is floating around, and given the right environment (such as certain seasons or overcrowded areas) and host, we can see a flare-up. We do expect, because of the vaccine and previous infections as well, that there will be some level of immunity. So, mostly we are not taking this as seriously as we would a new organism.' Also Read | WHO sees 'incredibly low' COVID-19, flu vaccination rates as cases surge However, Dr. Karpagam urges constant monitoring of the situation as the virus is a new mutation, and although there are fewer chances of another pandemic, it cannot be said for certain. 'We thought polio was contained, but suddenly it surged and that was because it was a new form of polio. So, lab checking, taking samples, and constant research must be done,' she added. Several groups in India remain particularly vulnerable: the elderly; those with underlying health conditions such as cardiovascular disease, lung or respiratory illnesses, diabetes, hypertension, or obesity; immunocompromised individuals, including cancer patients and transplant recipients; pregnant women due to physiological changes; and children under five, especially the unvaccinated. During any spike in respiratory infections, individuals in these categories are advised to take precautions: wear masks in public, avoid crowded areas, stay home when possible, and practise regular hand hygiene. Dr. Karpagam urges a more proactive public health system. 'We need a public health system that is prepared. We have to be able to prevent diseases before they occur, instead of waking up on the day of [the disease spreading] and trying to find a cure. It's a big problem in India. In the case of COVID, in case it rises, in case there are new mutations, just how prepared are we? That system of prevention and preparedness is not at all there.' In response to the recent surge, the Centre conducted facility-level mock drills on June 5 to assess hospital preparedness. These followed technical review meetings chaired by the Director General of Health Services, Sunita Sharma. States were instructed to ensure the availability of oxygen, isolation beds, ventilators, and essential medicines. A separate drill on June 2 tested oxygen supply systems, including PSA plants, LMO tanks, and MGPS lines. Hospitals have been directed to follow the revised ABC Guidelines 03, issued in June 2023, for treating patients with COVID-19 and influenza symptoms. All patients with symptoms of ILI (Influenza-Like Illness), ARI (Acute Respiratory Infection), or SARI (Severe Acute Respiratory Infection) must be tested. If a Rapid Antigen Test returns negative, an RT-PCR is mandatory. District RT-PCR facilities must be fully utilised, the department said. Preventive strategies remain familiar, but their urgency has returned. Respiratory viruses tend to be seasonal, with recurring waves. Vulnerable individuals—or anyone with symptoms—are advised to avoid crowded, enclosed, poorly ventilated spaces such as buses, trains, planes, offices, malls, and cinemas, especially without a mask. While rapid testing is widely available in urban areas, rural access remains limited, prompting calls for expanded distribution. Dr. Karpagam stressed the importance of vigilance—not just against the virus, but also against misinformation. 'If the virus is a mild version, pharmaceutical companies may hike the vaccine prices and say they have modified the vaccine to treat the mutation, and it becomes a business. Which is why we need research, labs, the Indian Council of Medical Research, and we need the government to put out regular statements. If it's a very serious mutation, then the government must put out notices regarding a vaccine and guidelines on how to manage symptoms. When there is no central regulation, then random people step in and give out misinformation to try various treatments without any scientific backing.' Global cases also climbing On May 28, 2025, the World Health Organization (WHO) reported a global increase in SARS-CoV-2 activity based on its Global Influenza Surveillance and Response System. Test positivity rates have risen steadily since mid-February, reaching 11 per cent—levels not observed since July 2024. This surge is concentrated in the Eastern Mediterranean, Southeast Asia, and Western Pacific regions and is being driven by new subvariants including LF.7, XFG, JN.1, and NB.1.8.1. Of these, NB.1.8.1 has caught WHO's attention and has been designated a Variant Under Monitoring (VUM). As of late April, 518 sequences of this variant had been reported across 22 countries, accounting for 10.7 per cent of global submissions. While the variant appears to spread more rapidly, WHO has found no evidence of increased severity. Symptoms remain largely familiar: sore throat, fever with chills, congestion, fatigue, and headache. Dr. Soumya Swaminathan, former chief scientist of WHO and chairperson of the M.S. Swaminathan Research Foundation, said such spikes of infections are normal. 'Like any other respiratory viral infection, it's self-resolving. Yes, there's an increase, and periodically we can expect to see an increase—I think every six to eight months is what it seems to be from looking back.' 'What we've seen in the past is that every time there are some additional mutations which confer an increase in transmissibility, you do see a spike, because the immunity that we have does not protect us against infection. Whether it's a vaccine or whether it's naturally induced immunity, it only protects us against severe diseases. So, infections are occurring, but the majority of them seem to be mild or do not require any hospitalisation or inpatient care or any specific treatment,' she added. A 2024 study in Nature found that vaccines updated to target JN.1 or related sublineages such as KP.2 elicit robust neutralising antibody responses against JN.1 and its descendants, including KP.3.1.1, XEC, LF.7.2.1, and LP.8.1. However, neutralisation titres against these newer variants are slightly lower than against JN.1 itself, suggesting some immune escape but continued protection. A 2024 Eurosurveillance study published in The Lancet estimated that the XBB.1.5 vaccine—a precursor to JN.1-targeted versions—had a vaccine effectiveness of 41 per cent in adults aged 18–59 and 50 per cent in those aged 60–85 against JN.1 infection. Also Read | COVID-19 rates are rising again—what you need to know Dr. Swaminathan urged long-term investment in vaccine development. 'What are those priority pathogens? WHO has priority pathogens for 25 or 26 viral families. India could decide out of that which are those ones which are of most importance or threat to us. I think if we had that kind of a list for India, then the industry would be able to develop and stockpile a certain number of doses of vaccine. This has to be done in a sort of private-public partnership, just like it was done for COVID,' she said. WHO shifts strategy In May, WHO released two new guidance documents in response to the global spike: Strategic and Operational Plan for Coronavirus Disease Threat Management: 2025–2030; and Implementation of the International Health Regulations (2005): Extension of the Standing Recommendations for Covid-19. 'This plan sets out WHO's strategic and operational framework to support Member States in the sustained, integrated, evidence-based management of coronavirus disease threats, including Covid-19, Mers, and potential novel coronavirus diseases of public health importance,' the document states. WHO no longer recommends lockdowns or blanket travel bans. Instead, it advises targeted, evidence-based responses that do not disrupt daily life: early variant detection, focused vaccination campaigns, and stronger public communication.